Comparative pharmacoscintigraphic and pharmacokinetic evaluation of two new formulations of inhaled insulin in type 1 diabetic patients

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 80, Issue 1, 2012, Pages 4-13

  Depreter, F ^a   Burniat, A ^b   Blocklet, D ^b   Lacroix, S ^b   Cnop, M ^b   Fery, F ^b   Van Aelst, N ^a   Pilcer, G ^a   Deleers, M ^a   Goldman, S ^b   Amighi, K ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b ERASME HOSPITAL   (Belgium)

Author keywords

Bioavailability; Dry powder inhaler (DPI); Lipids; Lung deposition; Microparticles; Pulmonary delivery

Indexed keywords

INCELLIGENT; INSULIN; NEUTRAL INSULIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DIABETIC PATIENT; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG SOLUBILITY; DRUG TISSUE LEVEL; HUMAN; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; MAXIMUM PLASMA CONCENTRATION; PHARMACOKINETICS; TIME TO MAXIMUM PLASMA CONCENTRATION;

ABSORPTION; ADMINISTRATION, INHALATION; ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DIABETES MELLITUS, TYPE 1; EXCIPIENTS; FEMALE; HUMANS; INSULIN; LUNG; MALE; POWDERS; RADIONUCLIDE IMAGING; SOLUBILITY;

EID: 83955165895     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2011.09.015     Document Type: Article

References (56)

1. B.M. Cheung, K.L. Ong, S.S. Cherny, P.C. Sham, A.W. Tso, and K.S. Lam Diabetes prevalence and therapeutic target achievement in the United States 1999 to 2006 Am. J. Med. 122 2009 443 453
2. American Diabetes Association Standards of medical care in diabetes - 2010 Diabetes Care 33 Suppl. 1 2010 S11 S61
3. P.C. Richardson, and A.H. Boss Technosphere insulin technology Diabetes Technol. Ther. 9 Suppl. 1 2007 S65 S72
4. L. Heinemann, Influences on time-action profiles, in: Kirchheim (Ed.) Time-action Profiles of Insulin Preparations, Mainz, Germany, 2004, pp. 85-105.
5. G.A. Brunner, B. Balent, M. Ellmerer, L. Schaupp, A. Siebenhofer, J.H. Jendle, J. Okikawa, and T.R. Pieber Dose-response relation of liquid aerosol inhaled insulin in type I diabetic patients Diabetologia 44 2001 305 308 (Pubitemid 32234455)
6. D.B. Muchmore, B. Silverman, A. De La Pena, and J. Tobian The AIR® inhaled insulin system: system components and pharmacokinetic/glucodynamic data Diabetes Technol. Ther. 9 Suppl. 1 2007 S41 S46
7. M. Wolzt, A. De La Pena, P.-Y. Berclaz, F.S. Tibaldi, J.R. Gates, and D.B. Muchmore AIR inhaled insulin versus subcutaneous insulin Diabetes Care 31 4 2008 735 740
8. A.H. Boss, W. Yu, and K. Ellerman Prandial insulin: is inhaled enough? Drug Dev. Res. 69 2008 138 142
9. K. Rave, S. Bott, L. Heinemann, S. Sha, R.H.A. Becker, S.A. Willavize, and T. Heise Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin Diabetes Care 28 5 2005 1077 1082 (Pubitemid 40616616)
10. C.J. Bailey, and A.H. Barnett Inhaled insulin: new formulation, new trial Lancet 375 2010 2199 2201
11. R. Siekmeier, and G. scheuch Inhaled insulin - does it become reality? J. Physiol. Pharmacol. 59 Suppl. 6 2008 81 113
12. H. Lian, S.S. Steiner, R.D. Sofia, J.H. Woodhead, H.H. Wolf, H.S. White, G.S. Shen, C.A. Rhodes, and R.T. McCabe A self-complementary, self-assembling microsphere system: application for intravenous delivery of the antiepileptic and neuroprotectant compound felbamate J. Pharm. Sci. 89 7 2000 867 875
13. A. Pfützner, and T. Forst Pulmonary insulin delivery by means of the technosphere drug carrier mechanism Expert Opin. Drug Deliv. 2 6 2005 1097 1106 (Pubitemid 41701207)
14. F. Depreter, and K. Amighi Formulation and in vitro evaluation of highly dispersive insulin dry powder formulations for lung administration Eur. J. Pharm. Biopharm. 76 2010 454 463
15. G. Pilcer, and K. Amighi Formulation strategy and use of excipients in pulmonary drug delivery Int. J. Pharm. 392 1-2 2010 1 19
16. Y.-J. Son, and J.T. McConville Dissolution testing for inhalation formulations Inhalation 2 6 2008 8 11
17. R.H.A. Becker, S. Sha, A.D. Frick, and R.J. Fountaine The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin Diabetes Care 29 2 2006 277 282 (Pubitemid 44106504)
18. L. Heinemann, T. Traut, and T. Heise Time-action profile of inhaled insulin Diabetic Med. 14 1997 63 72
19. L. Heinemann, Time-action profiles obtained with inhalative insulin, in: Kirchheim (Ed.), Time-action Profiles of Insulin Preparations, Mainz, Germany, 2004, pp.106-120.
20. J. Thipphawong, B. Otulana, P. Clauson, J. Okikawa, and S.J. Farr Pulmonary insulin administration using the AERx insulin diabetes system Diabetes Technol. Ther. 4 2002 499 504
21. A. Himmelmann, J. Jendle, A. Mellen, A.H. Petersen, U.L. Dahl, and P. Wollmer The impact of smoking on inhaled insulin Diabetes Care 26 2003 677 682 (Pubitemid 36929327)
22. S.P. Newman, G.R. Pitcairn, P.H. Hirst, and L. Rankin Radionuclide imaging technologies and their use in evaluating asthma drug deposition in the lungs Adv. Drug Deliv. Rev. 55 2003 851 867 (Pubitemid 36776797)
23. G. Pilcer, J. Goole, B. Van Gansbeke, D. Blocklet, C. Knoop, F. Vanderbist, and K. Amighi Pharmacoscintigraphic and pharmacokinetic evaluation of tobramycin DPI formulations in cystic fibrosis patients Eur. J. Pharm. Biopharm. 68 2 2008 413 421
24. H.K. Chan Radiolabeling of Pharmaceutical Aerosols and γ-Scintigraphic Imaging for Lung Deposition, Encyclopedia of Pharmaceutical Technology 2002 Marcel Dekker New York pp. 2365-2374
25. T.C. Carvalho, J.I. Peters, and R.O. Williams Influence of particle size on regional lung deposition - what evidence is there? Int. J. Pharm. 2011 10.1016/j.ijpharm.2010.12.040
26. A. Clark, M.C. Kuo, S. Newman, P. Hirst, G. Pitcairn, and M. Pickford A comparison of the pulmonary bioavailability of powder and liquid aerosol formulations of salmon calcitonin Pharm. Res. 25 2008 583 1590
27. T. Sebti, G. Pilcer, B. Van Gansbeke, S. Goldman, A. Michils, F. Vanderbist, and K. Amighi Pharmacoscintigraphic evaluation of lipid dry powder budesonide formulations for inhalation Eur. J. Pharm. Biopharm. 64 1 2006 26 32 (Pubitemid 44142238)
28. S.P. Newman, and R. Wilding Gamma scintigraphy an in vivo technique for assessing the equivalence of inhaled products Int. J. Pharm. 170 1998 1 9 (Pubitemid 28473241)
29. S.P. Newman, G.R. Pitcairn, and P.H. Hirst A brief history of gamma scintigraphy J. Aerosol. Med. 14 2001 139 145 (Pubitemid 32744346)
30. T. Buclin Pharmacology Shayne Cox Gad, Clinical Trials Handbook 2009 John Wiley New Jersey 985 986
31. D.A. Harville Maximum likelihood approaches to variance component estimation and to related problems JASA 72 358 1977 320 338
32. J.L. Hodges, and E.L. Lehmann Estimation of location based on ranks Ann. Math. Statist. 34 1963 598 611
33. S. Sdraulig, R. Franich, R.A. Tinker, S. Solomon, R. O'Brien, and P.N. Johnston In vitro dissolution studies of uranium bearing material in simulated lung fluid J. Environ. Radioactiv. 99 2008 527 538 (Pubitemid 351312832)
34. F. Fischel-Ghodsian, L. Brown, E. Mathiowitz, D. Brandenburg, and R. Langer Enzymatically controlled drug delivery Proc. Natl. Acad. Sci. 85 1988 2403 2406 (Pubitemid 24315901)
35. H. Lakhiari, and D. Muller Insulin adsorption on coated silica based supports grafted with N-acetylglucosamine by liquid affinity chromatography J. Chromatogr. B 808 2004 35 41 (Pubitemid 38968678)
36. M. Mezzena, S. Scalia, P.M. Young, and D. Traini Solid lipid budesonide microparticles for controlled release inhalation therapy AAPS J. 11 4 2009 771 778
37. 2 Pharm. Res. 15 6 1998 889 896 (Pubitemid 28307831)
38. S. Bellary, and A.H. Barnett Inhaled insulin: new technology, new possibilities Int. J. Clin. Pract. 60 6 2006 728 734 (Pubitemid 43811654)
39. J.S. Skyler, P.A. Hollander, L. Jovanovic, S. Klioze, A. Krasner, R.J. Riese, J. Reis, P. Schwartz, and W. Duggan Safety and efficacy of inhaled human insulin (Exubera®) during discontinuation and readministration of therapy in adults with type 1 diabetes: a 3-year randomized controlled trial Diabetes Res. Clin. Pract. 82 2008 238 246
40. J. Rosenstock, D.L. Lorber, L. Gnudi, C.P. Howard, D.W. Bilheimer, P.-C. Chang, R.E. Petrucci, A.H. Boss, and P.C. Richardson Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial Lancet 375 2010 2244 2253
41. S. Newman, S. Malik, P. Hirst, G. Pitcairn, A. Heide, J. Pabst, A. Dinkelaker, and W. Fleischer Lung deposition of salbutamol in healthy human subjects from the MAGhaler dry powder inhaler Respir. Med. 96 2002 1026 1032 (Pubitemid 35386119)
42. S.P. Newman, I.R. Wilding, and P.H. Hirst Human lung deposition data: the bridge between in vitro and clinical evaluations for inhaled drug products? Int. J. Pharm. 208 2000 49 60
43. C. Dunbar, G. Scheuch, K. Sommerer, M. DeLong, A. Verma, and R. Batycky In vitro and in vivo dose delivery characteristics of large porous particles for inhalation Int. J. Pharm. 245 2002 179 189 (Pubitemid 35299903)
44. W.-I. Li, M. Perzl, J. Heyder, R. Langer, J.D. Brain, K.-H. Englmeier, R.W. Niven, and D.A. Edwards Aerodynamics and aerosol particle deaggregation phenomena in model oral-pharyngeal cavities J. Aerosol Sci. 27 8 1996 1269 1286 (Pubitemid 26388438)
45. B. Grgic, A.R. Martin, and W.H. Finlay The effect of unsteady flow rate increase on in vitro mouth-throat deposition of inhaled boluses J. Aerosol Sci. 37 2006 1222 1233 (Pubitemid 44442198)
46. T. Sebti, and K. Amighi Preparation and in vitro evaluation of lipidic carriers and fillers for inhalation Eur. J. Pharm. Biopharm. 63 2006 51 58
47. G. Pilcer, T. Sebti, and K. Amighi Formulation and characterization of lipid-coated tobramycin particles for dry powder inhalation Pharm. Res. 23 5 2006 931 940 (Pubitemid 43781401)
48. S. Schüle, T. Schulz-Fademrecht, P. Garidel, K. Bechtold-Peters, and W. Frieß Stabilization of IgG1 in spray-dried powders for inhalation Eur. J. Pharm. Biopharm. 69 2008 793 807
49. W. Wang Lyophilization and development of solid protein pharmaceuticals Int. J. Pharm. 203 2000 1 60 (Pubitemid 30627625)
50. C. Bosquillon, P.G. Rouxhet, F. Ahimou, D. Simon, C. Culot, V. Préat, and R. Vanbever Aerosolization properties, surface composition and physical state of spray-dried protein powders J. Control. Release 99 2004 357 367 (Pubitemid 39296905)
51. E. Potocka, R.A. Baughman, and H. Derendorf Population pharmacokinetic model of human insulin following different routes of administration J. Clin. Pharmacol. 2010 10.1177/0091270010378520
52. K. Rave, A. De La Pena, F.S. Tibaldi, L. Zhang, B.SilvermanM. Hausmann, L. Heinemann, and D.B. Muchmore AIR inhaled insulin in subjects with chronic obstructive pulmonary disease Diabetes Care 30 2007 1777 1782
53. R. Vanbever, J.D. Mintzes, J. Wang, J. Nice, D. Chen, R. Batycky, R. Langer, and D.A. Edwards Formulation and physical characterization of large porous particles for inhalation Pharm. Res. 16 11 1999 1735 1742 (Pubitemid 29530407)
54. Exubera: EPAR - Product Information Annex I - Summary of product Characteristics. (accessed on 08.07.11).
55. J.P. Cassidy, N. Amin, M. Marino, M. Gotfried, T. Meyer, K. Sommerer, and R.A. Baughman Insulin lung deposition and clearance following Technosphere® insulin inhalation powder administration Pharm. Res. 2011 10.1007/s11095-011- 0443-4
56. M. Delong, J. Wright, M. Dawson, T. Meyer, K. Sommerer, and C. Dunbar Dose delivery characteristics of the AIR® pulmonary delivery system over a range of inspiratory flow rates J. Aerosol Med. 18 4 2005 452 459 (Pubitemid 43038410)